Differential efficacy of cisplatin plus pemetrexed between L858R and Del-19 in advanced EGFR-mutant non-squamous non-small cell lung cancer

Lung cancer is now one of the most common malignancies in the world. An estimated 1.8 million new lung cancer patients were diagnosed in 2012, and accounted for about 13% of total newly-diagnosed cancer patients [1]. Approximately 80% of lung cancer is histologically non-small cell lung cancer (NSCLC); most patients are already unresectable on their initial diagnosis and are selected to receive chemotherapy. Platinum doublet regimens were once the primary therapeutic choice for advanced NSCLC, but cytotoxic chemotherapies’ progress has reached a plateau. However, epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have improved therapeutic outcomes of EGFR-mutant advanced NSCLC. Exon 19 deletion (Del-19) mutation and Leu858Arg (L858R) point mutation in exon 21 are the most common EGFR mutations in NSCLC. Several clinical randomized phase III trials have demonstrated that EGFR-mutant advanced NSCLC patients treated with EGFR-TKIs obtain a longer progression-free survival (PFS) than those treated with platinum-based chemotherapy [2–7].

Combined analysis of overall survival (OS) data from two randomized phase III trials, LUX-Lung 3 and LUX-Lung 6, showed that overall survival was improved with the 2nd generation EGFR-TKI afatinib (31.7 months) over standard chemotherapy (20.7 months) for patients with Del-19 mutant NSCLC (p = 0.0001) [8]. These results demonstrate afatinib achieved greater effect than standard chemotherapy for Del-19 patients as a whole. Conversely, OS of patients with L858R was not significantly different between afatinib (22.1 months) and standard chemotherapy (26.9 months) (p = 0.16). We suppose afatinib exerts greater efficacy in Del-19, and chemotherapy exerts greater efficacy in L858R (OS of Del-19 with chemotherapy: 20.7 months, L858R with chemotherapy: 26.9 months). PFS in L858R and Del-19 patients treated with cisplatin plus gemcitabine were almost equivalent in LUX Lung 6 (5.6 months, both). However, LUX-Lung 3 results suggested cisplatin plus pemetrexed promoted longer PFS in L858R patients (8.1 months) than in Del-19 patients (5.6 months) [9]. L858R patients treated with cisplatin plus pemetrexed may obtain greater PFS than in Del-19. However, there is no verified data on this subject, and the efficacy of cisplatin plus pemetrexed for L858R is unclear now.

In this study, we retrospectively examined the efficacy of cisplatin plus pemetrexed as first line chemotherapy according to EGFR mutation status: Del-19 and L858R, in advanced non-squamous NSCLC.

Pemetrexed was approved as a therapeutic drug for malignant mesotheliomas in the United States in February, 2004. For NSCLC, pemetrexed gained supplemental approval in August of that year [11]. Pemetrexed inhibits a folic acid-dependent metabolic pathway necessary for cell replication by replacing folic acid and disrupting cellular activity. Pemetrexed inhibits many enzymes: Thymidylate synthase (TS); Dihydrofolate reductase (DHFR); and Glycinate ribonucleotide formyltransferase (GARFT). Some reports indicate pemetrexed has greater efficacy in non-squamous cell carcinoma than in squamous cell carcinoma [12, 13]. This differential efficacy may be explained by the higher TS expression exhibited by squamous cell carcinoma. In squamous cell carcinoma, the higher expression of TS and activity of Skp2, the enzymes synthesizing thymidine monophosphate (TMP), decreases the efficacy of pemetrexed [14, 15].

Furthermore, in subgroup analysis of international clinical phase III trial (PROFILE1007) aimed at Anaplastic lymphoma kinase (ALK) positive advanced lung cancer, pemetrexed showed higher effect than docetaxel [16]. Shaw et al. reported ALK positive lung cancer minimally expresses TS, and pemetrexed may thus have greater efficacy [17]. Ren et al. reported low TS expression in EGFR-mutant NSCLC too [18]. Giovannetti et al. reported different TS gene expression level among six human NSCLC cell lines. Especially, NCI-H1650 (H1650) harboring EGFR mutations had lower TS gene expression than the other five NSCLC cell lines which expressed wild type EGFR [19]. Cells with EGFR mutations may have greater sensitivity to pemetrexed due to lower TS gene expression levels. However, EGFR mutation was not separated by Del-19 or L858R in these reports. Pemetrexed may exert greater efficacy on L858R patients if TS expression is lesser in L858R than in Del-19. Wu et al. reported pemetrexed-based chemotherapy showed a higher response and longer PFS in EGFR-mutant than in wild type [20]. These results may affirm our study. However, in these reports EGFR mutation was not separated by Del-19 or L858R as well, and no prospective study examining TS expression among differing EGFR-mutants has been reported.

According to preclinical data, X-ray crystallographic analysis of the domain revealed different protein conformations of Del-19 and L858R. Both vary in their activated stability by difference in conformation, and their continuation state of kinase activation after the disruption of dimerization is different also [21]. Reguart et al. reported that biological properties of Del19 and L858R mutations differ, with different patterns of EGFR amplification and EGFR autophosphorylation between cell lines containing each mutation [22]. Other experimental reports show that biomedically, L858R and Del-19 may be two different things [23, 24]. Carey et al. compared the proliferation abilities of induced wild type, Del-19, and L858R NR6 fibroblasts [25]. According to this report, there are differences in cell proliferation ability among wild type, Del-19 and L858R. Especially in Del-19, high cell proliferation ability has been confirmed. Therefore, Del-19 may be faster in progression speed than L858R. Accordingly, L858R and Del-19 may respond differently to pemetrexed.

Various resistance mechanisms to EGFR-TKI treatments, such as ErBB family receptor amplification or other RTK co-amplification may be involved in the differential efficacy between L858R and Del-19. Yu et al. reported that frequencies of Met-amplification and HER-amplification did not differ between L858R and Del-19, although sample size was small [26]. The possible differences between Del19 and L858R require further research.

In comparison with the results of LUX-Lung 3, PFS of our study was similar. In Del-19, PFS of LUX-Lung 3 was 5.6 months versus 5.52 months in our study. In L858R, PFS of LUX-Lung 3 was 8.1 months versus 9.42 months in our study. The results of our study showed reproducibility. Our study demonstrated significant difference in PFS between L858R and Del-19 treated with pemetrexed, but did not reveal significant difference in OS. EGFR-TKIs were administered post-pemetrexed in approximately 90% of each mutation type, and most have reported higher EGFR-TKI efficacy in Del-19 than in L858R [4–6, 8]. This “catch-up” effect may explain similar OS between L858R and Del-19. Our study covered wild type as reference group in this study. Wild type PFS was 4.62 months, in accordance with past reports [27]. In multivariate analysis of OS, a significant difference was found between recurrence and advaced (clinical stage IIIB or IV) NSCLC. Yoshioka et al. reported that recurrent lung cancer had good prognosis and our study agrees in this respect [28].

Our study presents a few limitations. First, it is retrospective. Second, our sample size is relatively small. However, we were able to examine and obtain pure data by only including first line cisplatin plus pemetrexed treated patients and excluding other regimens (for instance, carboplatin-based or addition of bevacizumab), mirroring the strict patient selection of LUX-Lung 3. Finally, we were not able to perform TS expression immunostaining to conclude any causal link between EGFR mutation type, TS expression and treatment efficacy in this study. Further studies are warranted.

This study is the first report showing a significantly greater efficacy of cisplatin plus pemetrexed in L858R than in Del-19 between EGFR-mutant NSCLC chemotherapy naïve patients. In this study, we examined cisplatin plus pemetrexed regimen in first line chemotherapy, similar to LUX-lung studies. In EGFR-mutant NSCLC, EGFR-TKIs are undoubtedly the premier therapy, with limitations. Third generation EGFR-TKI after acquired resistance to first or second generation EGFR-TKIs represents an efficacious treatment [29], but only in the roughly 50% of patients who express T790 M mutation [30]. Immunotherapy has also attracted investigation in NSCLC [31–33], but it has shown reduced efficacy against EGFR-mutants [34, 35]. Thus, cytotoxic chemotherapy still has a role in treating patients who cannot benefit from further EGFR-TKI exposure or immunotherapy. Furthermore, administering platinum doublet chemotherapy alternating with EGFR-TKI produced longer survivals among EGFR-mutants than EGFR-TKI alone [28]. In addition, some report that EGFR-mutants may be more likely to benefit from cytotoxic chemotherapy than wild type [36, 37].

Our study indicated better efficacy of cisplatin plus pemetrexed in L858R than in Del-19 patients. In EGFR-mutant NSCLC, EGFR-TKIs are undoubtedly the premier therapy. However, in second line or later settings, cisplatin plus pemetrexed regimen may confer higher efficacy for L858R patients.